Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Larotrectinib for Newly-Diagnosed High-Grade Glioma With NTRK Fusion in Children
NCT04655404Phase 1Recruiting
- Sponsor
- Nationwide Children's Hospital
- Start
- Apr 2021
- Primary completion
- Dec 2026
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 5
01
Overview
Phase 1, open-label trial of larotrectinib in glioma and diffuse intrinsic pontine glioma (DIPG) (2 cohorts), sponsored by Nationwide Children's Hospital. Primary endpoints: Disease control rate at 8 weeks, Treatment-related adverse events and 2 more. Started Apr 2021; status: recruiting.
02
Drugs
larotrectinib
03
Conditions
gliomadiffuse intrinsic pontine glioma (DIPG)
Beyond the preview
Go deeper on NCT04655404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04655404.